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Is there a need for a treatment  
for COVID-19-induced diabetes?
Epidemiological data show that patients with dia-
betes who are COVID-19-positive may have a higher 
risk of serious complications [1]. In addition, during 
SARS-CoV-2 infection glycemic normalization is more 
difficult to achieve, with the risk of complicating the 
clinical scenario even more. This evidence shows that 
the patient with COVID-19-positive diabetes is a com-
plex patient. SARS-CoV-2 uses the angiotensin 2 con-
verting enzyme (ACE2) receptors expressed in different 
tissues including pancreatic beta cells to enter cells. We 
can hypothesize [2] this is the mechanism underlying 
the alterations of glycemic homeostasis with the risk 
of damage to the patient with persistent diabetes and 
of inducing diabetes in patients without persistent 
metabolic disease. 
Some data also suggest a higher incidence of gly-
cemic dysregulation in patients with SARS pneumonia 
compared to those with pneumonia from other viral 
causes [3]. However, recent evidence has shown that 
SARS-CoV-2 also binds to DPP4/CD26 when it enters 
respiratory tract cells. In addition, another recent 
study has clearly reported a correlation between DPP4 
and ACE2, suggesting that both membrane proteins 
are relevant in the pathogenesis of virus entry [4, 5]. 
One could hypothesize the use of antidiabetic drugs 
to manage cases where there is COVID-19-induced 
glycemic dysregulation. In particular, the gliptin class 
may be the most indicated among antidiabetic drugs, 
for several reasons [6]. 
The inhibition of DPP4/CD26 could antagonize 
the mechanism of cellular penetration of the virus. 
In addition, gliptins, which are associated with anti-
inflammatory effects and reduction of overproduction 
of cytokines, are drugs that can ensure glycemic nor-
malization and have low risk of causing hypoglycemia. 
Epidemiological studies are necessary to confirm these 
hypotheses [7, 8].
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